Original Article: Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes

“Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes.”

October 2026

NEJM

Tamara K. Oser, MD, Professor of Family Medicine at CU Anschutz (DFM), is the first author of the high impact publication, “Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes,” published in the New England Journal of Medicine (NEJM)—one of the most prestigious general medical journals in the world. Co-authors include DFM faculty members Sean Oser, MD, MPH and E. Seth Kramer, DO, MPH.

The study was a multicenter, randomized controlled trial conducted at 22 primary care sites across the United States to evaluate the efficacy and safety of continuous glucose monitoring (CGM) in adults with type 2 diabetes who were not using insulin. The results showed that CGM use led to greater reductions in glycated hemoglobin (A1C) levels and a lower risk of hyperglycemia compared with routine care. These improvements were larger than expected and were comparable to, or even greater than, the benefits often seen with some diabetes medications, highlighting CGM as a promising tool for diabetes management in this population.

A Major Impact on Type 2 Diabetes Patient Care

Dr. Tamara Oser said she is hopeful that these findings will lead to increased access to CGM, allowing more people living with diabetes to benefit from technology.

“Most people with non-insulin requiring type 2 diabetes receive their care in primary care settings and it is particularly exciting to see research like this in the primary care space which also maximizes generalizability of these results. The results of this trial should provide the evidence needed to charge the American Diabetes Association Standards of Care to recommend CGM for all people with type 2 diabetes, whether they are on insulin or not. These recommendations often drive payer coverage of CGM and so I am hopeful that the results of this trial will expand access of CGM to many more people living with diabetes.”

She also credited the success of the study to the teamwork and dedication of fellow DFM researchers and members of the Primary Care Diabetes Lab (PCDL).

“I served as the overall Study PI/Clinical Lead of this multi-site, national trial. Seth Kramer served as Site Principal Investigator for The University of Colorado, and Sean Oser served as a Sub-Investigator for the University of Colorado,” said Dr. Tamara Oser. “It is particularly exciting to see research like this with strong local representation for the University of Colorado, our Department of Family Medicine, and the PCDL. Like with all of the research we conduct, we could not do it without our incredible and skilled research coordinators who are also acknowledged in the manuscript.”

Read more from this article.